查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990334

血液傳染病檢查市場：依產品、技術、應用和最終用戶分類－2026-2032年全球市場預測

Bloodstream Infection Testing Market by Product, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血液傳染病檢查市場價值將達到 13 億美元，到 2026 年將成長至 13.9 億美元，到 2032 年將達到 22.2 億美元，複合年成長率為 7.93%。

主要市場統計數據
基準年 2025 13億美元
預計年份：2026年 13.9億美元
預測年份 2032 22.2億美元
複合年成長率 (%) 7.93%

全面概述臨床需求、檢查室操作和診斷技術創新如何融合，從而改變血液傳染病檢查的實踐。

血液感染疾病仍然是急診和公共衛生領域面臨的核心挑戰，因此迫切需要更準確、快速且與臨床緊密結合的診斷方法。近年來，診斷方法已從逐步改進檢查室技術轉向更廣泛地強調快速、可操作的診斷結果，以直接指導合理使用抗生素和患者管理。臨床醫生和檢查室管理人員在審查通訊協定時，會優先考慮那些既能縮短標靶治療時間，又能維持嚴格的品質和合規性標準的解決方案。

對推動血液感染疾病診斷快速發展和新途徑引入的技術、臨床和監管轉折點進行策略分析。

血液傳染病檢查領域正經歷著一場變革，這主要得益於技術進步、臨床路徑的演變以及監管部門為實現更快、更便捷的診斷而採取的措施。生物感測器設計、分子診斷和質譜分析的創新各自具有獨特的優勢。生物感測器簡化了樣本製備，並可實現快速檢測，通常可在床邊進行。分子診斷提高了病原體鑑定的敏感度和準確性。質譜分析可在既定的檢查室工作流程中提供可靠的物種層級鑑定。總而言之，這些技術正在拓展臨床醫生和實驗室技術人員可選擇的檢測方案。

評估 2025 年關稅變化將如何影響整個血液傳染病檢查生態系統的供應鏈韌性、籌資策略和營運計畫。

近期關稅調整與貿易政策考量，特別是已宣布或正在考慮的2025年相關政策，對診斷耗材、設備和組件的供應鏈產生了複雜的影響。關稅可能增加進口試劑、一次性耗材和專用設備零件的到貨成本，這將波及整個採購週期和庫存策略。為此，檢測實驗室和製造商正在加快審查籌資策略，加強國內庫存緩衝，並對替代供應商進行認證，以減少對單一供應商的依賴。

從詳細的細分觀點，識別產品類型、平台技術、醫療保健環境和應用需求之間的交集，進而影響採用和投資決策。

有效的市場區隔揭示了臨床需求、技術能力和商業性機會的交集，而從產品、技術、最終用戶和應用等不同層面捕捉細微差異的觀點，則能凸顯清晰的市場採納模式。按產品分析，儀器吸引了尋求處理能力和自動化程度的中心檢查室的投資；試劑和試劑盒成為耗材管理和經常性收入模式的重點；而軟體則日益成為支撐連接、分析和決策支援的基礎。每個產品類型都需要不同的服務模式和檢驗標準，進而影響採購和生命週期管理決策。

區域比較評估解釋了報銷方案、監管重點和醫療保健服務模式如何影響血液感染疾病診斷的引入和部署。

區域趨勢塑造了需求模式和創新路徑，美洲、歐洲、中東和非洲以及亞太地區的營運重點各不相同。在美洲，醫療保健系統優先考慮將新的診斷方法快速整合到臨床通訊協定和以價值為導向的醫療服務計劃中，這些計劃旨在獎勵可驗證結果的改善。因此，人們越來越關注能夠在臨床環境中提供可操作結果，同時又能維持檢查室級品質的確認性檢測解決方案。

以產業為重點，檢驗領先的診斷設備公司如何調整其產品、夥伴關係和證據策略，以加速產品部署並確保營運彈性。

主要企業正在重新定義其策略，以應對速度和準確性的兩大挑戰，同時投資於能夠確保供應連續性和客戶成功的服務模式。一些企業專注於垂直整合的解決方案，將儀器與專有試劑和數據分析相結合，從而更精準地管理性能和生命週期收入。另一些企業則優先考慮開放平台互通性和策略夥伴關係，以加速市場准入並降低現有設備在不同檢查室中的應用門檻。

為診斷開發人員和醫療保健領導者提供可操作且優先的建議，以增強血液傳染病檢查的供應彈性、臨床整合和證據產生。

產業領導者應採取務實的態度，平衡短期營運需求與長期技術投資，以維持臨床工作的連續性和競爭優勢。優先考慮可整合到現有工作流程中的模組化解決方案，可以減少對檢查室運作的干擾，並減輕檢驗負擔。同時，有針對性地投資自動化和試劑效率提升，有助於保護營運免受供應波動的影響。同樣重要的是，要建立多供應商籌資策略和完善的供應商選擇程序，避免依賴單一供應商，並在市場變化中保持偵測能力。

我們透明、以證據為基礎的調查方法，整合了同儕審查的研究、監管分析和相關人員訪談，確保了可靠、可操作的見解。

本執行摘要的研究整合了同行評審文獻、監管指導文件、行業白皮書以及對臨床檢查室負責人、技術開發人員和採購專家的訪談，以確保多角度的觀點。臨床檢驗研究和通訊協定審查的證據與營運報告和供應鏈分析進行了交叉比對，以全面反映技術性能和營運挑戰。受訪者涵蓋了不同的醫療機構，包括急診醫院檢查室、參考中心和照護現場環境，以確保研究結果能反映各種營運限制。

總之，該總結強調，改善血液感染疾病診斷結果的途徑需要技術創新、運作韌性和證據生成三者結合。

整體而言，血液傳染病檢查領域正朝著更靈活、整合和實證的模式轉變，強調快速獲得臨床可用的檢測結果，同時保持嚴格的分析性能和品管標準。涵蓋生物感測器、培養系統、質譜和分子診斷等技術的多樣性，為應對不同的臨床應用場景提供了互補的工具，而最成功的應用將是那些能夠將技術優勢與目標醫療環境的實際操作相結合的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：血液傳染病檢查市場：依產品分類

  • 裝置
  • 試劑和試劑盒
  • 軟體

第9章：血液傳染病檢查市場：依技術分類

  • 生物感測器平台
    • 電化學生物感測器
    • 光學生物感測器
  • 基於文化的系統
    • 自動化培養系統
    • 手工培養方法
  • 質譜分析
  • 分子診斷
    • 次世代定序
    • PCR

第10章：血液傳染病檢查市場：依應用領域分類

  • 臨床診斷
  • 研究
  • 監視與監測

第11章：血液傳染病檢查市場：依最終用戶分類

  • 學術和研究機構
  • 醫院檢查室
  • 即時檢測
  • 參考實驗室

第12章：血液傳染病檢查市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：血液傳染病檢查市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：血液傳染病檢查市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血液傳染病檢查市場

第16章：中國血液傳染病檢查市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Hardy Diagnostics
  • HiMedia Laboratories Pvt. Ltd.
  • Hologic, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Molzym
  • OpGen, Inc.
  • Qiagen NV
  • Siemens Healthineers AG
  • Sysmex Corporation
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4D00F1312BD4

The Bloodstream Infection Testing Market was valued at USD 1.30 billion in 2025 and is projected to grow to USD 1.39 billion in 2026, with a CAGR of 7.93%, reaching USD 2.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.30 billion
Estimated Year [2026] USD 1.39 billion
Forecast Year [2032] USD 2.22 billion
CAGR (%) 7.93%

A comprehensive situational overview describing how clinical demand, laboratory operations, and diagnostic innovation are converging to transform bloodstream infection testing practices

Bloodstream infections remain a central challenge for acute care and public health, driving urgent demands on diagnostic accuracy, speed, and clinical integration. Over recent years, the diagnostic landscape has shifted from incremental laboratory improvements to a broader emphasis on rapid, actionable results that can directly inform antimicrobial stewardship and patient management. As clinicians and laboratory leaders reassess protocols, they prioritize solutions that shorten time to targeted therapy while maintaining rigorous quality and compliance standards.

The adoption of advanced diagnostics is reshaping workflows, with laboratories balancing the need for high-throughput capacity alongside the demand for near-patient testing in emergency and critical care environments. At the same time, research institutions and reference laboratories continue to push technical boundaries, validating new biomarkers and sequencing approaches that promise deeper etiological insights. These changes are occurring in a context of constrained budgets, heightened regulatory scrutiny, and supply chain sensitivities, which together create both obstacles and incentives for innovative providers.

Consequently, stakeholders must consider a diverse set of factors when evaluating diagnostic strategies: analytical performance, integration with electronic health records and laboratory information systems, operational impact on staffing and turnaround times, and the ability to support surveillance and public health reporting. The resulting priorities emphasize not only technological capability but also usability, interoperability, and proven clinical utility across varied care settings.

A strategic analysis of the technological, clinical, and regulatory inflection points driving rapid evolution and new adoption pathways in bloodstream infection diagnostics

The landscape of bloodstream infection testing is undergoing transformative shifts driven by converging technological advances, evolving clinical pathways, and regulatory momentum toward faster, more actionable diagnostics. Innovations in biosensor design, molecular methods, and mass spectrometry are each contributing distinct advantages: biosensors enable rapid, often bedside detection with reduced sample preparation; molecular diagnostics offer enhanced sensitivity and pathogen identification precision; and mass spectrometry provides robust species-level identification in established laboratory workflows. Taken together, these technologies are expanding the palette of options available to clinicians and laboratorians.

Alongside technical progress, there is a sustained clinical trend toward earlier targeted therapy, underpinned by growing antimicrobial stewardship programs that demand diagnostic evidence to justify narrower-spectrum treatments. This creates a feedback loop: as diagnostics deliver actionable results more quickly, clinical protocols adjust to leverage those results, which in turn drives demand for even faster and more integrated testing solutions. Regulatory frameworks and reimbursement policies are beginning to reflect this shift, increasingly rewarding demonstrable improvements in patient outcomes and system efficiencies rather than raw throughput alone.

Operationally, laboratories are rethinking workflows to incorporate modular testing strategies that balance central laboratory capacity with decentralized point-of-care options. Interoperability with laboratory information systems and electronic health records has become a critical enabler of rapid result distribution and decision support. At the same time, developers and providers are paying closer attention to usability, automation, and supply continuity to reduce the burden on constrained clinical teams. These combined forces are not only changing product roadmaps but also influencing procurement criteria, partnership models, and long-term clinical adoption pathways.

An evaluation of how 2025 tariff shifts have reshaped supply chain resilience, procurement strategies, and operational planning across the bloodstream infection testing ecosystem

Recent tariff adjustments and trade policy considerations, especially measures announced or contemplated in 2025, have created a complex overlay on supply chains for diagnostic consumables, instruments, and components. Tariffs can increase landed costs for imported reagents, single-use disposables, and specialized instrument parts, which then reverberate across procurement cycles and inventory strategies. Laboratories and manufacturers have responded by reassessing sourcing strategies, increasing onshore inventory buffers, and accelerating qualification of alternative suppliers to mitigate single-source dependencies.

These dynamics have practical implications for procurement timelines and capital allocation. Buyers may shift toward longer contracts with domestic or tariff-exempt suppliers, preferring predictable supply terms over marginal cost advantages. Meanwhile, manufacturers face pressure to optimize manufacturing footprints, balance production between domestic and international sites, and adjust pricing structures to preserve commercial viability without undermining customer relationships. In some cases, tariffs have incentivized localized assembly or component manufacturing to reduce exposure to cross-border levies and promote supply resilience.

Beyond direct cost implications, tariff-driven realignments affect innovation velocity and collaboration models. Companies may defer noncritical upgrades or slow international rollouts while reassessing cost models. Conversely, some organizations accelerate investments in automation and reagent efficiency to lower per-test variable costs and sidestep tariff escalations. For clinical laboratories, the cumulative impact has been a renewed focus on operational flexibility: multi-vendor procurement strategies, increased validation of platform interchangeability, and strategic stockpiling where feasible to avoid diagnostic interruptions. These adaptations aim to preserve clinical continuity while managing budgetary constraints and regulatory compliance amid an evolving trade environment.

A detailed segmentation-driven perspective revealing where product classes, platform technologies, care settings, and application needs intersect to influence adoption and investment decisions

Effective segmentation reveals where clinical need, technical capability, and commercial opportunity intersect, and a nuanced view across product, technology, end user, and application slices illuminates distinct adoption patterns. When analyzed by product, instruments attract investments from centralized laboratories seeking throughput and automation, reagents and kits are focal for consumables management and recurring revenue models, and software increasingly underpins connectivity, analytics, and decision support. Each product category demands different service models and validation criteria, influencing procurement and lifecycle management decisions.

Considering technology, biosensor platforms offer rapid, often near-patient detection and are evolving along electrochemical and optical modalities that favor different sample types and use cases. Culture based systems remain foundational for pathogen isolation and susceptibility testing, with automated culture systems streamlining workflow and manual culture methods retaining relevance in resource-constrained settings. Mass spectrometry, particularly MALDI ToF MS, has become a workhorse for species identification where laboratory throughput and accuracy are paramount. Molecular diagnostics, including next generation sequencing and PCR, deliver deep pathogen characterization and resistance profiling, supporting both clinical decision-making and surveillance objectives.

From an end-user perspective, academic and research institutes continue to advance method development and validation studies, hospital laboratories focus on integrating rapid diagnostics into care pathways to reduce length of stay and improve outcomes, point of care testing brings immediacy to emergency and critical care settings where time is critical, and reference laboratories concentrate on specialized testing, confirmation, and epidemiological support. Application-driven segmentation differentiates clinical diagnosis needs from research priorities and surveillance and monitoring obligations, each with distinct performance, throughput, and regulatory demands. Understanding these intersecting segments helps stakeholders prioritize investments that match technical strengths to user needs and application constraints.

A comparative regional assessment describing how reimbursement, regulatory priorities, and healthcare delivery models shape the adoption and deployment of bloodstream infection diagnostics

Regional dynamics shape both demand patterns and innovation pathways, with distinct operational priorities in the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems emphasize rapid integration of new diagnostics into clinical protocols and value-based care initiatives that reward demonstrable outcome improvements. This drives interest in solutions that can provide actionable results at the point of care while maintaining laboratory-level quality for confirmatory testing.

In Europe, Middle East & Africa, regulatory harmonization efforts and national public health priorities guide procurement and adoption, and there is marked interest in diagnostics that can support surveillance networks and antimicrobial resistance monitoring across diverse care environments. Meanwhile, Asia-Pacific exhibits strong demand for scalable, cost-efficient testing solutions that can meet both high-volume urban centers and resource-limited rural settings. Market participants across all regions are negotiating trade-offs between centralized high-throughput platforms and decentralized rapid tests to optimize clinical pathways and resource utilization.

Across geographies, interoperability with health IT infrastructure, supply chain robustness, and local manufacturing considerations influence deployment strategies. Regional reimbursement frameworks and public health policy also determine how quickly novel diagnostics move from validation to routine use, with some jurisdictions prioritizing immediate clinical impact and others focusing on longer-term surveillance capabilities. These regional nuances require tailored commercial approaches and regulatory planning to ensure successful technology adoption and sustained clinical integration.

An industry-focused examination of how leading diagnostics organizations are aligning product, partnership, and evidence strategies to accelerate uptake and secure operational resilience

Leading players are redefining their strategies to address the dual imperatives of speed and accuracy while also investing in service models that ensure supply continuity and customer success. Some firms are concentrating on vertically integrated solutions that pair instruments with proprietary reagents and data analytics, enabling a tighter control of performance and lifecycle revenue. Others prioritize open-platform interoperability and strategic partnerships that accelerate market access and lower barriers to adoption for laboratories with diverse existing equipment.

Collaboration between technology providers, clinical networks, and academic centers is becoming more common, as companies seek real-world evidence and validation studies that demonstrate clinical utility and support regulatory submissions. Investment in software and informatics capabilities is another notable trend: advanced laboratory information management integration, result interpretation algorithms, and antimicrobial stewardship decision support are increasingly valued additions to core diagnostic offerings. Companies are also exploring business models that reduce upfront capital burdens for customers, including reagent-as-a-service or outcome-linked agreements, to facilitate uptake in budget-constrained environments.

In parallel, many organizations are enhancing their global supply chain strategies to mitigate tariff exposure and logistical disruptions. This includes diversifying supplier bases, locating critical manufacturing closer to key markets, and strengthening distribution partnerships. Together, these strategic moves reflect a competitive environment where differentiation rests on a combination of technological performance, evidence generation, customer support, and operational reliability.

Practical, prioritized recommendations for diagnostic developers and healthcare leaders to strengthen supply resilience, clinical integration, and evidence generation for bloodstream infection testing

Industry leaders should adopt a pragmatic approach that balances near-term operational needs with long-term technological investments to preserve both clinical continuity and competitive advantage. Prioritizing modular solutions that can be integrated into existing workflows reduces disruption and lowers validation overhead for laboratories, while investing selectively in automation and reagent efficiency helps insulate operations from supply volatility. Equally important is building multi-vendor procurement strategies and robust supplier qualification programs to avoid single-source dependencies and to sustain testing capacity during market shifts.

Strategic partnerships with clinical networks and academic collaborators will accelerate real-world evidence generation, which in turn supports regulatory submissions and payer dialogues. Investing in software and interoperability pays dividends by improving result routing, analytics, and stewardship integration; these capabilities enhance clinical utility and create stickiness for customers. Finally, scenario-based planning for trade and tariff impacts - including localized manufacturing where feasible and flexible contracting models - will reduce operational risk and preserve access to critical consumables during periods of policy uncertainty.

A transparent and evidence-driven methodology integrating peer-reviewed research, regulatory analysis, and stakeholder interviews to ensure robust and actionable insights

The research underpinning this executive summary synthesized peer-reviewed literature, regulatory guidance documents, industry white papers, and interviews with clinical laboratory leaders, technology developers, and procurement specialists to ensure a rounded perspective. Evidence from clinical validation studies and protocol reviews was cross-checked against operational reports and supply chain analyses to understand both technical performance and real-world implementation challenges. Interview subjects were selected to represent a diversity of care settings, including acute hospital laboratories, reference centers, and point-of-care environments, ensuring that findings reflect varied operational constraints.

Where possible, technical claims and adoption trends were corroborated by independent publications and regulatory filings to avoid reliance on promotional materials. The methodology prioritized transparency in source selection and clearly documented assumptions related to technology capabilities, regulatory context, and logistical constraints. This approach provides readers with a defensible analytical foundation for decision-making while acknowledging areas where further primary research or longitudinal data would strengthen confidence in long-term trends.

A concluding synthesis highlighting the convergence of technological innovation, operational resilience, and evidence generation as the pathway to improved diagnostic outcomes in bloodstream infections

In aggregate, the field of bloodstream infection testing is moving toward a more agile, integrated, and evidence-driven model that privileges rapid, clinically actionable results while maintaining rigorous standards for analytical performance and quality control. Technological diversity-spanning biosensors, culture systems, mass spectrometry, and molecular diagnostics-offers complementary routes to address different clinical use cases, and the most successful implementations will be those that align technical strengths with the operational realities of the targeted care environment.

At the same time, external pressures such as tariff changes, supply chain fragility, and evolving reimbursement priorities underscore the need for flexible procurement strategies and resilient operational planning. Organizations that invest in interoperability, real-world evidence generation, and strategic supplier relationships will be better positioned to deliver consistent diagnostic value. Ultimately, the path to improved patient outcomes hinges on aligning product innovation with clinical workflows, regulatory requirements, and pragmatic commercial models that enable sustainable adoption across diverse healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bloodstream Infection Testing Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software

9. Bloodstream Infection Testing Market, by Technology

  • 9.1. Biosensor Platforms
    • 9.1.1. Electrochemical Biosensors
    • 9.1.2. Optical Biosensors
  • 9.2. Culture Based Systems
    • 9.2.1. Automated Culture Systems
    • 9.2.2. Manual Culture Methods
  • 9.3. Mass Spectrometry
  • 9.4. Molecular Diagnostics
    • 9.4.1. Next Generation Sequencing
    • 9.4.2. PCR

10. Bloodstream Infection Testing Market, by Application

  • 10.1. Clinical Diagnosis
  • 10.2. Research
  • 10.3. Surveillance & Monitoring

11. Bloodstream Infection Testing Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Hospital Laboratories
  • 11.3. Point Of Care Testing
  • 11.4. Reference Laboratories

12. Bloodstream Infection Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bloodstream Infection Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bloodstream Infection Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Bloodstream Infection Testing Market

16. China Bloodstream Infection Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Accelerate Diagnostics, Inc.
  • 17.7. Beckman Coulter, Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. bioMerieux SA
  • 17.11. Bruker Corporation
  • 17.12. Cepheid
  • 17.13. Danaher Corporation
  • 17.14. DiaSorin S.p.A.
  • 17.15. F. Hoffmann-La Roche AG
  • 17.16. Grifols S.A.
  • 17.17. Hardy Diagnostics
  • 17.18. HiMedia Laboratories Pvt. Ltd.
  • 17.19. Hologic, Inc.
  • 17.20. Luminex Corporation
  • 17.21. Meridian Bioscience, Inc.
  • 17.22. Molzym
  • 17.23. OpGen, Inc.
  • 17.24. Qiagen N.V.
  • 17.25. Siemens Healthineers AG
  • 17.26. Sysmex Corporation
  • 17.27. T2 Biosystems, Inc.
  • 17.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ELECTROCHEMICAL BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY OPTICAL BIOSENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MANUAL CULTURE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CLINICAL DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SURVEILLANCE & MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BLOODSTREAM INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY BIOSENSOR PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY CULTURE BASED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BLOODSTREAM INFECTION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)